arrow
A

Ana Huerta

Clínica Universidad de Navarra
H指数:23
被引数:2,009

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MASLD INFLAMMATORY PHENOTYPING USING LIPIDOMICS AND SUBCLINICAL CORONARY ATHEROSCLEROSIS: A PILOT STUDY

MASLD的炎症表型分析:基于脂质组学和亚临床冠状动脉粥样硬化的初步研究

2026-01-010
OAAI
Real-world experience of Iptacopan in C3 glomerulopathy

Iptacopan在C3肾小球病中的真实世界经验

2025-10-010
OAAI
Elevated pre-eclampsia risk in lupus nephritis and antiphospholipid syndrome: a nationwide Spanish registry analysis

系统性红斑狼疮肾炎和抗磷脂综合征中妊娠期高血压风险的升高:一项全国性西班牙登记研究

2025-09-010
PRE
Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

finerenone在心力衰竭患者中的临床实用性和安全性: 精细注册的原理和设计

2025-02-010
OAAI
Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy

免疫复合物膜增生性肾小球肾炎和C3肾小球病中蛋白尿与纵向结局的对比分析

2025-01-011
OAAI
Genetic testing in focal segmental glomerulosclerosis: to whom and when?
2023-08-105
OAAI
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy
2023-06-1961
PRE
Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy
2023-03-305
OAAI
Anti-glomerular Basement Membrane Glomerulonephritis: A Study in Real Life
2022-07-0511
OAAI
Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy
2022-04-286
OAAI
Validation of a Histologic Scoring Index for C3 Glomerulopathy
2021-05-0125
PRE
Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease
2020-08-1942
OAAI
Complement Activation and Thrombotic Microangiopathies

补体激活与血栓性微血管病

2019-11-0670
OAAI